In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Homology Medicines Inc (FIXX). The company’s shares opened today at $19.96.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 6.5% and a 45.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Allogene Therapeutics Inc.
Currently, the analyst consensus on Homology Medicines Inc is a Moderate Buy with an average price target of $18.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.40 and a one-year low of $15.07. Currently, Homology Medicines Inc has an average volume of 107.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
